Clinical trials
Pancreatic Adenocarcinoma clinical trials
Below are recruiting pancreatic adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 348 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06893536Recruiting
Nutrition and recovery after pancreatic cancer surgery
This study looks at how nutrition before and after surgery affects recovery for people with pancreatic cancer that can be removed. By reviewing medical records of past patients, researchers hope to learn how to better support patients through their treatment.
StrasbourgAges 18 years+ - NCT06998940RecruitingPhase 3
Chemotherapy with or without panitumumab for pancreatic cancer
This trial tests whether adding a targeted drug called panitumumab to standard chemotherapy can help people with a certain type of pancreatic cancer that has spread. It is for patients whose tumors do not have a KRAS mutation and who have already had one line of chemotherapy.
Anchorage, AlaskaAges 18 years+ - NCT07089940RecruitingEarly Phase 1
OMO-103 for advanced pancreatic cancer
This trial tests a new drug called OMO-103 in people with advanced pancreatic cancer that has spread or cannot be removed by surgery. It may be an option whether you have had treatment before or not, as long as it's been at least 2 weeks since your last therapy.
Portland, OregonAges 18 years+ - NCT07126158RecruitingPhase 2
Radiation plus targeted drugs for advanced pancreatic cancer
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
St Louis, MissouriAges 18 years+ - NCT07148830Recruiting
Surgery technique study for pancreatic cancer patients
This trial tests a specific surgical method called mesopancreatic excision during Whipple surgery for pancreatic cancer. It may help remove more cancer tissue and improve outcomes for patients with resectable disease.
Minya, Minya GovernorateAges 18–75 - NCT07226856RecruitingPhase 2
New combo for advanced pancreatic cancer
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
Scottsdale, ArizonaAges 18 years+ - NCT07243262Recruiting
Breath test for pancreatic cancer detection
This trial tests whether a simple breath test can help detect pancreatic cancer earlier. If you have been referred for possible pancreatic cancer, you may be able to take part.
LondonAges 18 years+ - NCT07269626RecruitingPhase 2
PULSAR therapy for pancreatic cancer
This trial tests whether adding a special type of radiation therapy (PULSAR) to standard chemotherapy can help control pancreatic cancer that has not spread far. It is for people who have already completed a few rounds of chemo without their cancer growing.
Seoul, Select Province/StateAges 19 years+ - NCT07284277RecruitingPhase 1/Phase 2
TTFields and chemo for metastatic pancreatic cancer
This trial tests a wearable device (TTFields) combined with a specific chemotherapy (mFOLFIRINOX) for people whose pancreatic cancer has spread to the liver and other organs. The device sends gentle electrical fields to disrupt cancer cell growth, and the chemo attacks cancer cells throughout the body.
Pamplona, NavarreAges 18 years+ - NCT07259317RecruitingPhase 2
Relacorilant plus chemo for metastatic pancreatic cancer
This trial tests adding a drug called relacorilant to standard chemotherapy (nab-paclitaxel and gemcitabine) for people with pancreatic cancer that has spread. The goal is to see if this combination works better than chemo alone.
Scottsdale, ArizonaAges 18 years+ - NCT06229496RecruitingPhase 1
Study of GAS for newly diagnosed advanced pancreatic cancer
This trial tests an oral medication called GAS in people with pancreatic cancer that has spread to other parts of the body, who have not yet received any treatment for metastatic disease. The goal is to find the best dose and see how well it works.
Chiayi CityAges 18 years+ - NCT04926467RecruitingPhase 2
Chemo plus anakinra for pancreatic cancer
This Phase 2 study tests whether adding anakinra (an immune signal blocker) to standard chemotherapy can improve outcomes for some people with pancreatic ductal adenocarcinoma. It’s mainly for adults with stage I–III disease who have enough organ function and are able to come in for treatment and follow-up.
Dallas, TexasAges 18 years+ - NCT06988150Recruiting
SIBO and weight loss in pancreatic cancer
This study looks at whether a condition called SIBO (too many bacteria in the small intestine) is linked to weight loss in people with pancreatic cancer. You might join if you have pancreatic cancer and have lost weight recently.
Los Angeles, CaliforniaAges 18 years+ - NCT05356039Recruiting
Study of surgery options and quality of life in pancreatic cancer
This study looks at people with borderline-resectable or locally advanced pancreatic cancer to see how treatment choices affect survival, quality of life, and whether tumors can be removed by surgery. It may help doctors better predict who can benefit from surgical approaches and what outcomes matter most to patients.
UmeåAges 18 years+ - NCT06790602RecruitingPhase 2
Cemiplimab plus gemcitabine for metastatic pancreatic cancer
This trial tests a combination of an immunotherapy drug (cemiplimab) and chemotherapy (gemcitabine) for people with pancreatic cancer that has spread to other parts of the body. It is for those whose tumors have specific genetic changes (in the SWI/SNF genes) and have only had one prior treatment that was not immunotherapy.
La Jolla, CaliforniaAges 18 years+ - NCT06896188RecruitingPhase 1
Study of 9-ING-41 and retifanlimab plus chemo for advanced pancreatic cancer
This trial tests a new combination of two experimental drugs (9-ING-41 and retifanlimab) plus a standard chemotherapy regimen (modified FOLFIRINOX) for people with advanced or metastatic pancreatic cancer who have not yet received treatment for their advanced disease. The goal is to see if this combination is safe and effective.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07262957RecruitingPhase 4
Preventing complications after pancreatic surgery with a drug bundle
This trial tests whether giving a combination of three treatments—hydrocortisone (a steroid), octreotide (a drug that reduces digestive fluids), and a tissue patch—before and during pancreatic surgery can help prevent complications. It is for people with a very small pancreatic duct (3 mm or less) who are scheduled for pancreatic surgery.
AmsterdamAges 18 years+ - NCT06041009Recruiting
Pancreatic cancer screening with a new enzyme test
This study is testing if measuring a substance called elastase-1, along with standard tests, can help find pancreatic cancer earlier. It may benefit people who already have signs of pancreatic disease or are at high risk.
Jinan, ShandongAges 18 years+ - NCT07252076Recruiting
MRI for detecting hidden liver metastases in pancreatic cancer
This trial uses an MRI scan to look for small liver metastases that may not be visible on a CT scan in people newly diagnosed with pancreatic cancer. It aims to improve the accuracy of staging before treatment begins.
Alessandria, PiedmontAges 18 years+ - NCT06261359RecruitingPhase 2
CEND-1 plus chemo for first-line pancreatic cancer
This trial tests a new drug called CEND-1 combined with standard chemotherapy for people with advanced pancreatic cancer that has not been treated before. It aims to see if the combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18–80 - NCT07163273RecruitingPhase 2
Alternating chemotherapy for first-line metastatic pancreatic cancer
This study tests a monthly rotation of two chemotherapy combinations (NALIRIFOX and GnP) as the first treatment for metastatic pancreatic cancer. The goal is to see if alternating the drugs helps control the cancer while reducing side effects.
Bay Shore, New YorkAges 18 years+ - NCT06048484RecruitingPhase 2
Combination therapy for localized pancreatic cancer
This trial tests a combination of drugs for people with localized pancreatic cancer who have already completed 8 cycles of modified FOLFIRINOX chemotherapy before surgery. The goal is to see if adding these drugs after chemo and radiation helps improve outcomes.
Lake Success, New YorkAges 18 years+ - NCT06320717Recruiting
AI-guided pre-surgery treatment for pancreatic cancer
This study tests how well an AI tool can guide which pre-surgery treatment is best for people with pancreatic cancer that can be removed. It uses your tumor's genetic fingerprint to choose the most effective therapy.
Buffalo, New YorkAges 18 years+ - NCT06831136RecruitingPhase 2
Endoscopic ultrasound ablation plus immunotherapy for pancreatic cancer
This trial tests a combination of endoscopic ultrasound-guided heat ablation (RFA) and the immunotherapy drug pembrolizumab for people with locally advanced or metastatic pancreatic cancer that cannot be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
Houston, TexasAges 18 years+
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma?
- Yes. Clin2 currently lists 348 recruiting pancreatic adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Borderline Resectable Pancreatic Adenocarcinoma
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.